Age and risks of FDA-approved long-acting β2-adrenergic receptor agonists

Pediatrics

Volumn 128, Issue 5, 2011, Pages

  McMahon, Ann W ^a   Levenson, Mark S ^b   McEvoy, Bradley W ^b   Mosholder, Andrew D ^c   Murphy, Dianne ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Office of Translational Sciences   (United States)

^c Center for Drug Evaluation and Research   (United States)

Author keywords

Asthma; Death; Hospitalization; Meta analysis

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; PLACEBO;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASTHMA; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HOSPITALIZATION; HUMAN; INCIDENCE; INTUBATION; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD;

EID: 80355131209     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-1720     Document Type: Article

References (18)

1. Stolley PD. Asthma mortality: why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis. 1972;105(6):883-890
2. Beasley R. A historical perspective of the New Zealand asthma mortality epidemics. J Allergy Clin Immunol. 2006;117(1):225-228
3. Grainger J, Woodman K, Pearce N, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further casecontrol study. Thorax. 1991;46(2):105-111
4. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993;306(6884):1034-1037
5. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial, a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15-26 (Pubitemid 43265239)
6. Levenson M. Long-Acting Beta-Agonists and Adverse Asthma Events Metaanalysis. Silver Spring, MD: Food and Drug Administration; Briefing for Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee and Pediatric Advisory Committee on December 10-11, 2008. Available at: www.fda.gov/ohrms/dockets/ac/08/briefing/2008- 4398b1-01-FDA.pdf. Accessed October 6, 2011
7. GlaxoSmithKline. Serevent Diskus (Salmeterol Xinafoate Inhalation Powder) Prescribing Information. Research Triangle Park, NC: GlaxoSmithKline; 2010. Available at: www.accessdata.fda.gov/drugsatfda-docs/label/2010/020692s036lbl. pdf. Accessed October 6, 2011
8. Benjamin DK, Smith B, Sun JM, et al. Safety and transparency of pediatric drug trials. Arch Pediatr Adolesc Med. 2009;163(12):1080-1086
9. Benjamin DK, Smith PB, Murphy MD, et al. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA. 2006;296(10):1266- 1273 (Pubitemid 44394898)
10. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics. 1985;41(1):55- 68
11. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd ed. Lippincott, Williams & Wilkins; 2008
12. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting β-agonists on severe asthma exacerbations and asthma related deaths. Ann Intern Med. 2006;144(12):904-912 (Pubitemid 46768131)
13. Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2008;(4):CD006923
14. Weatherall M, Wijesinghe M, Perrin K, Harwood M, Beasley R. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax. 2010;65(1):39-43
15. Bateman E, Nelson H, Bousquet J, et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med. 2008;149(1):33-42
16. Salpeter SR, Wall AJ, Buckley NS. Long-acting β-agonists with and without inhaled corticosteroids and catastrophic asthma events. Am J Med. 2010;123(4):322-328
17. Nelson H, Bonuccelli C, Radner F, et al. Safety of formoterol in patients with asthma: combined analysis of data from double-blind, randomized controlled trials. J Allergy Clin Immunol. 2010;125(2):390-396
18. Food and Drug Administration. Long-acting beta-agonists (LABAs): new safe use requirements, June 3, 2010. Available at: www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm201003.htm. Accessed December 15, 2010